From: Lack of a synergistic effect of a non-viral ALS gene therapy based on BDNF and a TTC fusion molecule
Group | (n) | Gastrocnemius muscle | Plantar muscle | ||
---|---|---|---|---|---|
Latency (ms) | CMAP (mV) | Latency (ms) | CMAP (mV) | ||
3 months | |||||
WT | (6) | 0.93 ± 0.04 | 51.9 ± 2.2 | 1.66 ± 0.08 | 6.49 ± 0.47 |
SOD control | (6) | 1.11 ± 0.05 | 27.8 ± 2.9* | 2.00 ± 0.10 | 2.55 ± 0.57* |
SOD BDNF | (7) | 1.12 ± 0.05 | 32.1 ± 5.0 | 1.89 ± 0.08 | 2.69 ± 0.44* |
SOD TTC | (6) | 1.04 ± 0.02 | 28.6 ± 3.5 | 1.95 ± 0.07 | 3.10 ± 0.52* |
SOD BDNF-TTC | (8) | 1.10 ± 0.05 | 32.1 ± 7.4 | 2.01 ± 0.11 | 2.64 ± 0.47* |
4 months | |||||
WT | (6) | 0.93 ± 0.05 | 53.6 ± 4.2 | 1.59 ± 0.03 | 6.89 ± 0.79 |
SOD control | (5) | 1.09 ± 0.04 | 13.0 ± 2.6* | 1.98 ± 0.03 | 0.89 ± 0.35* |
SOD BDNF | (5) | 1.10 ± 0.06 | 18.1 ± 3.1* | 1.88 ± 0.04 | 1.52 ± 0.41* |
SOD TTC | (5) | 1.06 ± 0.03 | 18.7 ± 4.8* | 2.03 ± 0.15* | 1.91 ± 0.83* |
SOD BDNF-TTC | (5) | 1.11 ± 0.07 | 20.9 ± 9.3* | 2.02 ± 0.16* | 1.68 ± 0.71* |